Related Experiment Videos
Gentamicin pharmacokinetics in patients with malignancies
J S Bertino1, L A Booker, P Franck
1Department of Pharmacy Services, Mary Imogene Bassett Hospital, Cooperstown, New York 13326.
Antimicrobial Agents and Chemotherapy
|July 11, 1991
Summary
Gentamicin pharmacokinetics in leukemia patients showed faster drug clearance, but overall, malignancies did not alter gentamicin drug clearance. Initial creatinine clearance was the key differentiator in leukemic patients.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Oncology
Background:
- Gentamicin is an antibiotic commonly used in cancer patients.
- Understanding gentamicin pharmacokinetics is crucial for optimizing dosing and efficacy.
- Malignancies may potentially alter drug metabolism and excretion.
Purpose of the Study:
- To investigate the pharmacokinetics of gentamicin in patients with leukemia, other malignancies, and no malignancies.
- To determine if malignancy status affects gentamicin drug clearance.
- To assess the predictive value of creatinine clearance for gentamicin pharmacokinetics.
Main Methods:
- Retrospective analysis of 880 patients' data.
- Inclusion of patients with leukemia, other malignancies, and control groups.
- Calculation of creatinine clearance and gentamicin clearance.
Main Results:
- Leukemia patients exhibited significantly faster gentamicin clearance compared to other groups.
- No significant pharmacokinetic differences were observed between patients with other malignancies and those without malignancies.
- Initial calculated creatinine clearance was the primary differing factor in leukemic patients.
Conclusions:
- Malignancy, in general, does not appear to alter gentamicin pharmacokinetics.
- Leukemia patients demonstrate unique pharmacokinetic profiles regarding gentamicin clearance.
- Creatinine clearance is a critical factor in assessing gentamicin disposition, particularly in leukemic individuals.